Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | IL1RN | P18510 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 3/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193673 | 1.00 | DRD2 (0.43) | DRD2DRD3IL1RNERAP2ERAP1 | |
| SCHEMBL20185074 | 0.84 | IL1RN (0.50) | DRD2DRD3IL1RNERAP2ERAP1 | |
| SCHEMBL16290564 | 0.84 | DRD2 (0.35) | DRD2DRD3IL1RNERAP2ERAP1 | |
| SCHEMBL16290376 | 0.84 | DRD2 (0.39) | DRD2DRD3IL1RNERAP2ERAP1 | |
| SCHEMBL16290480 | 0.84 | DRD2 (0.39) | DRD2DRD3IL1RNERAP2ERAP1 | |
| SCHEMBL18646271 | 0.81 | DRD2 (0.33) | DRD2DRD3IL1RNERAP2ERAP1 | |
| SCHEMBL18646270 | 0.80 | DRD2 (0.42) | DRD2DRD3EPAS1AADATHTR1A | |
| SCHEMBL18518606 | 0.80 | DRD2 (0.33) | DRD2DRD3 | |
| SCHEMBL18428856 | 0.80 | DRD2 (0.33) | DRD2DRD3CYP11B1CYP11B2 | |
| SCHEMBL18482077 | 0.80 | EPAS1 (0.37) | DRD2DRD3EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2178880-B1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARM INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-2402334-B1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARM INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-1989206-B1 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1989206-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007092213-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DRD2 4856/4885DRD3 4844/4885IL1RN 459/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DRD2 4856/4885DRD3 4844/4885IL1RN 459/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DRD2 4856/4885DRD3 4844/4885IL1RN 459/4885 |
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885IL1RN 2421/4885 |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, STS | DRD2 4622/4885DRD3 4604/4885IL1RN 2422/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | DRD2 4856/4885DRD3 4844/4885IL1RN 459/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4691/4885DRD3 4681/4885IL1RN 2421/4885 |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | DRD2 4695/4885DRD3 4677/4885IL1RN 2602/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | DRD2 4856/4885DRD3 4844/4885IL1RN 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.